Epigenetic control of gene expression: Potential implications for cancer treatment

Critical Reviews in Oncology/Hematology

Volumn 111, Issue , 2017, Pages 166-172

  Perri, F ^a   Longo, F ^b   Giuliano, M ^c,d   Sabbatino, F ^e   Favia, G ^f   Ionna, F ^b   Addeo, R ^g   Della Vittoria Scarpati, G ^a   Di Lorenzo, G ^c   Pisconti, S ^a  

^a Medical Oncology SS: Annunziata H   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF SALERNO   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g SAN GIOVANNI DI DIO HOSPITAL   (Italy)

Author keywords

Cancer; Epigenetics; Oncogenes; Therapy; Tumor suppressor genes

Indexed keywords

AZACITIDINE; BELINOSTAT; BORTEZOMIB; DECITABINE; DEXAMETHASONE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; PANOBINOSTAT; PLACEBO; ROMIDEPSIN; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR;

ANEMIA; CANCER THERAPY; CARDIOTOXICITY; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DIARRHEA; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG TARGETING; EPIGENETICS; FATIGUE; GENE EXPRESSION; GENE SILENCING; HODGKIN DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; ONCOGENE; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; CARCINOGENESIS; GENETIC EPIGENESIS; GENETICS; NEOPLASMS; PROMOTER REGION;

CARCINOGENESIS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 85014106272     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2017.01.020     Document Type: Review

References (74)

1. Argos, M., Chen, L., Jasmine, F., Tong, L., Pierce, B.L., Roy, S., Paul-Brutus, R., Gamble, M.V., Harper, K.N., Parvez, F., Rahman, M., Rakibuz-Zaman, M., Slavkovich, V., Baron, J.A., Graziano, J.H., Kibriya, M.G., Ahsan, H., Gene-specific differential DNA methylation and chronic arsenic exposure in an epigenome-wide association study of adults in Bangladesh. Environ. Health Perspect. 123:January (1) (2015), 64–71.
2. Bernstein, B.E., Meissner, A., Lander, E.S., The mammalian epigenome. Cell 128:February (4) (2007), 669–681.
3. Bernt, K.M., Armstrong, S.A., Targeting epigenetic programs in MLL-rearranged leukemias. Hematol. Am. Soc. Hematol. Educ. Progr. 2011 (2011), 354–360.
4. Braun, C.J., Hemann, M.T., Rewiring the solid tumor epigenome for cancer therapy. Expert Rev. Anticancer Ther. 16:September (9) (2016), 977–987.
5. Brown, J.M., Giaccia, A.J., The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58:7 (1998), 1408–1416.
6. Brunetto, A.T., Ang, J.E., Lal, R., Olmos, D., Frentzas, S., Mais, A., Hauns, B., Mollenhauer, M., Lahu, G., de Bono, J.S., A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. J. Clin. Oncol., 27(May (15 Suppl.)), 2009, 3530.
7. Chen, Q.W., Zhu, X.Y., Li, Y.Y., Meng, Z.Q., Epigenetic regulation and cancer (review). Oncol. Rep. 31:February (2) (2014), 523–532.
8. Chistiakov, D.A., Myasoedova, V.A., Orekhov, A.N., Bobryshev, Y.V., Epigenetically active drugs inhibiting DNA methylation and histone deacetylation. Curr. Pharm. Des., 2016, October.
9. Cohen, Y., Singer, G., Lavie, O., Dong, S.M., Beller, U., Sidransky, D., The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin. Cancer Res. 9:August (8) (2003), 2981–3298.
10. Della Vittoria Scarpati, G., Calura, E., Di Marino, M., Romualdi, C., Beltrame, L., Malapelle, U., Troncone, G., De Stefano, A., Pepe, S., De Placido, S., D'Incalci, M., Marchini, S., Carlomagno, C., Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. Biomed. Res. Int., 2014, 2014, 840921.
11. Domer, P.H., Fakharzadeh, S.S., Chen, C.S., Jockel, J., Johansen, L., Silverman, G.A., Kersey, J.H., Korsmeyer, S.J., Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc. Natl. Acad. Sci. U. S. A. 90:August (16) (1993), 7884–7888.
12. Elliott, M.A., Letendre, L., Tefferi, A., Hogan, W.J., Hook, C.C., Pruthi, R., Kaufmann, S.H., Pardanani, A.D., Begna, K., Ashrani, A., Wolanskyj, A.P., Al-Kali, A., Litzow, M.R., Therapy-related acute promyelocytic leukemia (t-APL): observations on APL pathogenesis. J. Clin. Oncol., 29(May (15 Suppl.)), 2011, 6567.
13. Esteller, M., Epigenetics in cancer. N. Engl. J. Med. 358:11 (2008), 1148–1150.
14. Esteller, M., Gaidano, G., Goodman, S.N., Zagonel, V., Capello, D., Botto, B., Rossi, D., Gloghini, A., Vitolo, U., Carbone, A., Baylin, S.B., Herman, J.G., Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94:January (1) (2002), 26–32.
15. Gao, D., Herman, J.G., Guo, M., The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget 7:June (24) (2016), 37331–37346.
16. Gołąbek, K., Strzelczyk, J.K., Wiczkowski, A., Michalski, M., Potential use of histone deacetylase inhibitors in cancer therapy. Contemp. Oncol. (Pozn.) 19:6 (2015), 436–440.
17. Gollin, S.M., Cytogenetic alterations and their molecular genetic correlates in head and neck squamous cell carcinoma: a next generation window to the biology of disease. Genes Chromosomes Cancer 53:December (12) (2014), 972–990.
18. Hamamoto, R., Nakamura, Y., Dysregulation of protein methyltransferases in human cancer: an emerging target class for anticancer therapy. Cancer Sci. 107:April (4) (2016), 377–384.
19. Hamamoto, R., Silva, F.P., Tsuge, M., Nishidate, T., Katagiri, T., Nakamura, Y., Furukawa, Y., Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 97:February (2) (2006), 113–118.
20. Haydon, A.M., Jass, J.R., Emerging pathways in colorectal-cancer development. Lancet Oncol. 3:February (2) (2002), 83–88.
21. He, W., Li, X., Xu, S., Ai, J., Gong, Y., Gregg, J.L., Guan, R., Qiu, W., Xin, D., Gingrich, J.R., Guo, Y., Chang, G., Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. Biochem. Biophys. Res. Commun. 435:June (4) (2013), 526–532.
22. Horwitz, S.M., Coiffier, B., Foss, F.M., Prince, H.M., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., Pinter-Brown, L.C., Padmanabhan, S., Shustov, A.R., Nichols, J., Balser, J., Carroll, S., Pro, B., Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). J. Clin. Oncol., 29(May (15 Suppl.)), 2011, 8033.
23. Huang, Y.Q., Guan, H., Liu, C.H., Liu, D.C., Xu, B., Jiang, L., Lin, Z.X., Chen, M., Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis. Genet. Mol. Res., 15(April (2)), 2016.
24. Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., van Lohuizen, M., Nakauchi, H., Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21:December (6) (2004), 843–851.
25. Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128:February (4) (2007), 683–692.
26. Jones, B., Su, H., Bhat, A., Lei, H., Bajko, J., Hevi, S., Baltus, G.A., Kadam, S., Zhai, H., Valdez, R., Gonzalo, S., Zhang, Y., Li, E., Chen, T., The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet., 4(September (9)), 2008, e1000190.
27. Kaminskas, E., Farrell, A.T., Wang, Y.C., Sridhara, R., Pazdur, R., FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10:March (3) (2005), 176–182.
28. Kantarjian, H.M., O'Brien, S., Huang, X., Garcia-Manero, G., Ravandi, F., Cortes, J., Shan, J., Davisson, J., Bueso-Ramos, C.E., Issa, J.P., Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109:March (6) (2007), 1133–1137.
29. Kristiansen, S., Nielsen, D., Sölétormos, G., Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer. Clin. Epigenet., 8(April), 2016, 35.
30. Ksiaa, F., Ziadi, S., Amara, K., Korbi, S., Trimeche, M., Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clin. Chim. Acta 404:June (2) (2009), 128–133.
31. Kurdistani, S.K., Histone modifications in cancer biology and prognosis. Prog. Drug Res. 67 (2011), 91–106.
32. Lee, M.N., Tseng, R.C., Hsu, H.S., Chen, J.Y., Tzao, C., Ho, W.L., Wang, Y.C., Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin. Cancer Res. 13:February (3) (2007), 832–838.
33. Lee, H.Z., Kwitkowski, V.E., Del Valle, P.L., Ricci, M.S., Saber, H., Habtemariam, B.A., Bullock, J., Bloomquist, E., Li Shen, Y., Chen, X.H., Brown, J., Mehrotra, N., Dorff, S., Charlab, R., Kane, R.C., Kaminskas, E., Justice, R., Farrell, A.T., Pazdur, R., FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin. Cancer Res. 21:June (12) (2015), 2666–2670.
34. Leung, W.K., Man, E.P., Yu, J., Go, M.Y., To, K.F., Yamaoka, Y., Cheng, V.Y., Ng, E.K., Sung, J.J., Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach. Clin. Cancer Res. 12:May (10) (2006), 3216–3221.
35. Li, B., Carey, M., Workman, J.L., The role of chromatin during transcription. Cell 128:February (4) (2007), 707–719.
36. Li, Y., Sun, L., Zhang, Y., Wang, D., Wang, F., Liang, J., Gui, B., Shang, Y., The histone modifications governing TFF1 transcription mediated by estrogen receptor. J. Biol. Chem. 286:April (16) (2011), 13925–13936.
37. Lübbert, M., Rüter, B.H., Claus, R., Schmoor, C., Schmid, M., Germing, U., Kuendgen, A., Rethwisch, V., Ganser, A., Platzbecker, U., Galm, O., Brugger, W., Heil, G., Hackanson, B., Deschler, B., Döhner, K., Hagemeijer, A., Wijermans, P.W., Döhner, H., A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 97:March (3) (2012), 393–401.
38. Luger, K., Mäder, A.W., Richmond, R.K., Sargent, D.F., Richmond, T.J., Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389:September (6648) (1997), 251–260.
39. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., Pazdur, R., FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:October (10) (2007), 1247–1252.
40. Meissner, A., Mikkelsen, T.S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., Zhang, X., Bernstein, B.E., Nusbaum, C., Jaffe, D.B., Gnirke, A., Jaenisch, R., Lander, E.S., Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:August (7205) (2008), 766–770.
41. Mendell, J.T., miRiad roles for the miR-17-92 cluster in development and disease. Cell 133:April (2) (2008), 217–222.
42. Mercatelli, N., Coppola, V., Bonci, D., Miele, F., Costantini, A., Guadagnoli, M., Bonanno, E., Muto, G., Frajese, G.V., De Maria, R., Spagnoli, L.G., Farace, M.G., Ciafrè, S.A., The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE, 3(12), 2008, e4029.
43. Millward, M., Price, T., Townsend, A., Sweeney, C., Spencer, A., Sukumaran, S., Longenecker, A., Lee, L., Lay, A., Sharma, G., Gemmill, R.M., Drabkin, H.A., Lloyd, G.K., Neuteboom, S.T., McConkey, D.J., Palladino, M.A., Spear, M.A., Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. New Drugs 30:December (6) (2012), 2303–2317.
44. Mountzios, G., Rampias, T., Psyrri, A., The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Ann. Oncol. 25:October (10) (2014), 1889–1900.
45. Nervi, C., De Marinis, E., Codacci-Pisanelli, G., Epigenetic treatment of solid tumours: a review of clinical trials. Clin. Epigenet., 7(December), 2015, 127.
46. Neumann, A.S., Sturgis, E.M., Wei, Q., Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol. Carcinog. 42:February (2) (2005), 65–92.
47. Otterson, G.A., Khleif, S.N., Chen, W., Coxon, A.B., Kaye, F.J., CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 11:September (6) (1995), 1211–1216.
48. Parrella, P., Poeta, M.L., Gallo, A.P., Prencipe, M., Scintu, M., Apicella, A., Rossiello, R., Liguoro, G., Seripa, D., Gravina, C., Rabitti, C., Rinaldi, M., Nicol, T., Tommasi, S., Paradiso, A., Schittulli, F., Altomare, V., Fazio, V.M., Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin. Cancer Res. 10:August (16) (2004), 5349–5354.
49. Perri, F., Pacelli, R., Della Vittoria Scarpati, G., Cella, L., Giuliano, M., Caponigro, F., Pepe, S., Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck 37:May (5) (2015), 763–770.
50. Prayer Galetti, T., D'Arrigo, L., De Zorzi, L., Patarnello, T., [Heredity in renal and prostatic neoplasia]. Arch. Ital. Urol. Androl. 69:September (4) (1997), 241–246.
51. Prigge, E.S., Arbyn, M., von Knebel Doeberitz, M., Reuschenbach, M., Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. Int. J. Cancer, 2016, November.
52. Ramachandran, S., Ient, J., Göttgens, E.L., Krieg, A.J., Hammond, E.M., Epigenetic therapy for solid tumors: highlighting the impact of tumor hypoxia. Genes (Basel) 6:September (4) (2015), 935–956.
53. Rouhi, A., Mager, D.L., Humphires, R.K., Kuchenbauer, F., MiRNAs, epigenetics, and cancer. Mamm. Genome 19:August (7–8) (2008), 517–525.
54. Saito, M., Schetter, A.J., Mollerup, S., Kohno, T., Skaug, V., Bowman, E.D., Mathé, E.A., Takenoshita, S., Yokota, J., Haugen, A., Harris, C.C., The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin. Cancer Res. 17:April (7) (2011), 1875–1882.
55. San-Miguel, J.F., Lonial, S., Hungria, V., Moreau, P., Einsele, H., Lee, J.H., Yoon, S., Corradini, P., Jedrzejczak, W.W., Tan, D.C., Yong, K., Guenther, A., Wroclawska-Swacha, M.M., Weber, H.J., Bourquelot, P.M., Richardson, P.G., PANORAMA1: a randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. J. Clin. Oncol., 29(May (15 Suppl.)), 2011, TPS227.
56. Seligson, D.B., Horvath, S., McBrian, M.A., Mah, V., Yu, H., Tze, S., Wang, Q., Chia, D., Goodglick, L., Kurdistani, S.K., Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174:May (5) (2009), 1619–1628.
57. Shen, L., Kondo, Y., Rosner, G.L., Xiao, L., Hernandez, N.S., Vilaythong, J., Houlihan, P.S., Krouse, R.S., Prasad, A.R., Einspahr, J.G., Buckmeier, J., Alberts, D.S., Hamilton, S.R., Issa, J.P., MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst. 97:September (18) (2005), 1330–1338.
58. Sikand, K., Slaibi, J.E., Singh, R., Slane, S.D., Shukla, G.C., miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int. J. Cancer 129:August (4) (2011), 810–819.
59. Spurling, C.C., Godman, C.A., Noonan, E.J., Rasmussen, T.P., Rosenberg, D.W., Giardina, C., HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol. Carcinog. 47:February (2) (2008), 137–147.
60. Stefansson, O.A., Villanueva, A., Vidal, A., Martí, L., Esteller, M., BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 7:November (11) (2012), 1225–1229.
61. Strahl, B.D., Allis, C.D., The language of covalent histone modifications. Nature 403:January (6765) (2000), 41–45.
62. Suzuki, M.M., Bird, A., DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9:June (6) (2008), 465–476.
63. Takahashi, Y., Iwai, M., Kawai, T., Arakawa, A., Ito, T., Sakurai-Yageta, M., Ito, A., Goto, A., Saito, M., Kasumi, F., Murakami, Y., Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer 19:July (3) (2012), 242–252.
64. Thangaraju, M., Carswell, K.N., Prasad, P.D., Ganapathy, V., Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem. J. 417:January (1) (2009), 379–389, 10.1042/BJ20081132.
65. Trédan, O., Galmarini, C.M., Patel, K., Tannock, I.F., Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99:19 (2007), 1441–1454.
66. Tsuge, M., Hamamoto, R., Silva, F.P., Ohnishi, Y., Chayama, K., Kamatani, N., Furukawa, Y., Nakamura, Y., A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5′ flanking region of SMYD3 is a risk factor for human cancers. Nat. Genet. 37:October (10) (2005), 1104–1107.
67. Valenzuela, M.A., Canales, J., Corvalán, A.H., Quest, A.F., Helicobacter pylori-induced inflammation and epigenetic changes during gastric carcinogenesis. World J. Gastroenterol. 21:December (45) (2015), 12742–12756.
68. Venkatesh, S., Workman, J.L., Histone exchange, chromatin structure and the regulation of transcription. Nat. Rev. Mol. Cell Biol. 16:March (3) (2015), 178–189.
69. Wang, H., Ren, J., E-cadherin germline gene (CDH1) mutation in hereditary gastric carcinoma families. J. Clin. Oncol., 22(July (14 Suppl.)), 2004, 9634.
70. Wang, P., Tang, J.T., Peng, Y.S., Chen, X.Y., Zhang, Y.J., Fang, J.Y., XRCC1 downregulated through promoter hypermethylation is involved in human gastric carcinogenesis. J. Dig. Dis. 11:December (6) (2010), 343–351.
71. Wu, K., Xu, X.N., Chen, Y., Pu, X.L., Wang, B.Y., Tang, X.D., RASSF1A gene methylation is associated with nasopharyngeal carcinoma risk in Chinese. Asian Pac. J. Cancer Prev. 16:6 (2015), 2283–2287.
72. Yang, X., Karuturi, R.K., Sun, F., Aau, M., Yu, K., Shao, R., Miller, L.D., Tan, P.B., Yu, Q., CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE, 4(4), 2009, e5011.
73. Yang, L., Zhao, Z., Zhao, S., Chen, C., Cong, X., Li, Z., Ren, M., The clinicopathological significance of epigenetic silencing of VHL promoter and renal cell carcinoma: a meta-analysis. Cell. Physiol. Biochem. 40:6 (2016), 1465–1470.
74. Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P.L., Ong, T.C., Prince, H.M., Harrison, S.J., Kirschbaum, M., Johnston, P., Gallagher, J., Le Corre, C., Shen, A., Engert, A., Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J. Clin. Oncol. 30:June (18) (2012), 2197–2203.